For Investors

Immodulon is to open its next round of financing in H2-2022 to execute and expand its ambitious clinical trials programme. If interested, please contact us at:

At Immodulon we are dedicated to improving the lives of patients suffering from life-threatening cancers through novel therapies that boost their immune response and improve the performance of their cancer treatment. To support us in bringing these important treatments to market and enabling patients to live happier, healthier and longer lives – please contact us at: